These arrays are of the highest quality and offer excellent performance, ensuring you receive results you can trust.
Metabolic Syndrome is a clustering of cardiovascular risk factors. It is more common than you might think, with approximately 20-25% of adults affected; it certainly is a highly prevalent condition. Individuals with Metabolic Syndrome are three times more likely to have a stroke or heart attack and five times more likely to develop type 2 diabetes, this highlights the seriousness of the syndrome. The pathophysiological pathways which lead to this condition however, remain unclear. The IDF Metabolic Syndrome worldwide definition states that an individual must have central obesity plus at least two of the following four factors; raised triglycerides, reduced HDL cholesterol, raised blood pressure and raised fasting plasma glucose.
Metabolic Syndrome Array I includes these analytes; C-peptide, Ferritin, IL-1a, IL-6, Insulin, Leptin, Plasminogen Activator Inhibitor-I, Resistin and Tumour Necrosis Factor a. Metabolic Syndrome Array II includes; Adiponectin, CRP and Cystatin C. Utilising proven multiplexing Biochip technology, these arrays provide cost and time savings as multiple assays can be run on one sample. The Metabolic Syndrome Arrays are suitable for use on plasma and serum, using only 100 µl of sample to measure all analytes on each array. Randox also offer a complete range of multi-analyte controls and calibrators to ensure reliable results.
Contact Randox today and bring revolutionary metabolic testing to your laboratory.
For more information please visit www.randox.com or email marketing@randox.com
About Randox
Headquartered in the United Kingdom, Randox Laboratories Ltd. is a market leader within the in vitro diagnostics industry, manufacturing high quality diagnostic products for laboratories worldwide. Our extensive product portfolio offers complete solutions within the fields of clinical chemistry, cardiology, forensic toxicology, veterinary, drug residues, life sciences, oncology, molecular diagnostics and internal and external quality control. Our goal is to ‘revolutionise healthcare through continuously improving diagnostic solutions.’ We continue to achieve this year after year due to our commitment and significant re-investment in Research and Development. Our innovative approach to diagnostics allows us to develop revolutionary products, specifically designed to provide more efficient, higher quality and reliable results, ensuring patients receive the right diagnosis at the right time.
For more information contact us at marketing@randox.com
